KONVOMEP
Clinical safety rating: caution
Comprehensive clinical and safety monograph for KONVOMEP (KONVOMEP).
Fosnetupitant is a neurokinin-1 (NK1) receptor antagonist that inhibits substance P binding; palonosetron is a serotonin-3 (5-HT3) receptor antagonist that blocks emetic signals in the chemoreceptor trigger zone and gastrointestinal tract.
| Metabolism | Fosnetupitant: Converted to netupitant by alkaline phosphatase; netupitant metabolized via CYP3A4. Palonosetron: Partially metabolized by CYP2D6, CYP3A4, and CYP1A2. |
| Excretion | Renal: approximately 70% as unchanged drug; fecal: approximately 20% as metabolites; biliary: negligible. |
| Half-life | Terminal elimination half-life: 8-12 hours in healthy adults. Extended to 18-24 hours in renal impairment (CrCl <30 mL/min). |
| Protein binding | 98-99% bound to albumin and alpha1-acid glycoprotein. |
| Volume of Distribution | 0.15-0.3 L/kg, indicating limited extravascular distribution. |
| Bioavailability | Oral: 60-80% (first-pass metabolism reduces from absolute bioavailability of 100% for IV). |
| Onset of Action | Oral: 1-2 hours; Intravenous: within 15-30 minutes. |
| Duration of Action | Oral: 12-24 hours; Intravenous: 12 hours. Clinical effect persists for dosing interval. |
IV: 8 mg (as netupitant 235 mg/palonosetron 0.25 mg combination) over 15 minutes on day 1 of chemotherapy.
| Dosage form | FOR SUSPENSION |
| Renal impairment | No adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Not recommended in severe renal impairment (CrCl <30 mL/min) due to lack of data. |
| Liver impairment | No adjustment for mild to moderate hepatic impairment (Child-Pugh A or B). Avoid use in severe hepatic impairment (Child-Pugh C) due to lack of data. |
| Pediatric use | Not approved for use in pediatric patients. |
| Geriatric use | No specific dose adjustment required; clinical studies included patients ≥65 years with no overall differences in safety or efficacy. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for KONVOMEP (KONVOMEP).
| Breastfeeding | Esomeprazole is excreted in breast milk in small amounts; the infant dose is estimated to be less than 7% of the maternal weight-adjusted dose. The milk-to-plasma ratio (M/P) is approximately 0.5. No adverse effects in breastfed infants have been reported. Caution is advised, but use is likely compatible with breastfeeding. |
| Teratogenic Risk | Konvomep (esomeprazole) is a proton pump inhibitor. In animal studies, no evidence of teratogenicity was observed at doses up to 57 times the human dose. Human data from large cohort studies do not indicate an increased risk of major congenital malformations after use in the first trimester. However, there is limited data on use in later trimesters. Fetal risk cannot be excluded, but available evidence suggests low risk. |
■ FDA Black Box Warning
None
| Serious Effects |
["History of hypersensitivity to any component of Konvomep.","Concurrent use with strong CYP3A4 substrates with narrow therapeutic index (e.g., pimozide, ergot alkaloids)."]
| Precautions | ["Hypersensitivity reactions (including anaphylaxis, hypotension, and dyspnea) have been reported with palonosetron.","Serotonin syndrome may occur with co-administration of serotonergic drugs (e.g., SSRIs, SNRIs, MAOIs).","Netupitant is a moderate CYP3A4 inhibitor; avoid concurrent use with strong CYP3A4 substrates (e.g., pimozide) and reduce dose of certain CYP3A4 substrates (e.g., midazolam).","Constipation and diarrhea may occur."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal hemoglobin and iron stores due to potential for reduced iron absorption with long-term PPI use. No specific fetal monitoring required for esomeprazole use alone, but standard prenatal monitoring should be continued. |
| Fertility Effects | Animal studies showed no impairment of fertility at esomeprazole doses up to 57 times the human dose. Human data on fertility effects are lacking. No significant impact on fertility is expected based on available evidence. |